Progress in Biophysics and Molecular Biology, ISSN 0079-6107, 05/2019, Volume 143, pp. 1 - 4
Journal Article
Progress in Biophysics and Molecular Biology, ISSN 0079-6107, 05/2019, Volume 143, pp. 1 - 4
Journal Article
Progress in Biophysics and Molecular Biology, ISSN 0079-6107, 05/2019, Volume 143, pp. 1 - 4
Journal Article
Biophysical Journal, ISSN 0006-3495, 02/2016, Volume 110, Issue 3, pp. 538a - 538a
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 2014, Volume 13, Issue 3, pp. 217 - 236
The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more than half of all human tumours carrying mutations in this particular...
WILD-TYPE P53 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ACUTE MYELOGENOUS LEUKEMIA | DNA-BINDING COOPERATIVITY | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | CELL-CYCLE ARREST | INTERACTING PROTEIN KINASE-2 | ACUTE MYELOID-LEUKEMIA | SMALL-MOLECULE ANTAGONISTS | MDM2 ANTAGONIST NUTLIN-3 | TUMOR-SUPPRESSOR PATHWAY | Neoplasms - metabolism | Protein Structure, Tertiary | Tumor Suppressor Protein p53 - antagonists & inhibitors | Humans | Drug Discovery - trends | Tumor Suppressor Protein p53 - metabolism | Drug Discovery - methods | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Antineoplastic Agents - metabolism | Animals | Signal Transduction - drug effects | Signal Transduction - physiology | Tumor Suppressor Protein p53 - chemistry | Clinical Trials as Topic - methods | Protein Binding - physiology | Care and treatment | Pharmacology, Experimental | Tumor suppressor genes | Research | Protein-protein interactions | Testing | Cancer | Index Medicus
WILD-TYPE P53 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ACUTE MYELOGENOUS LEUKEMIA | DNA-BINDING COOPERATIVITY | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | CELL-CYCLE ARREST | INTERACTING PROTEIN KINASE-2 | ACUTE MYELOID-LEUKEMIA | SMALL-MOLECULE ANTAGONISTS | MDM2 ANTAGONIST NUTLIN-3 | TUMOR-SUPPRESSOR PATHWAY | Neoplasms - metabolism | Protein Structure, Tertiary | Tumor Suppressor Protein p53 - antagonists & inhibitors | Humans | Drug Discovery - trends | Tumor Suppressor Protein p53 - metabolism | Drug Discovery - methods | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Antineoplastic Agents - metabolism | Animals | Signal Transduction - drug effects | Signal Transduction - physiology | Tumor Suppressor Protein p53 - chemistry | Clinical Trials as Topic - methods | Protein Binding - physiology | Care and treatment | Pharmacology, Experimental | Tumor suppressor genes | Research | Protein-protein interactions | Testing | Cancer | Index Medicus
Journal Article
Progress in Biophysics and Molecular Biology, ISSN 0079-6107, 09/2017, Volume 128, pp. 1 - 2
Journal Article
Progress in Biophysics and Molecular Biology, ISSN 0079-6107, 09/2017, Volume 128, pp. 1 - 2
Journal Article
Progress in Biophysics and Molecular Biology, ISSN 0079-6107, 09/2017, Volume 128, pp. 1 - 2
Journal Article
Methods in Molecular Biology, ISSN 1064-3745, 2017, Volume 1656, pp. 89 - 102
MicroRNAs are small noncoding but functionally important RNA molecules that are involved in regulating diverse cellular, metabolic, and immune processes. Their...
miScript primer assay | PBMCs | Small RNAs | TaqMan MicroRNA assay | Leukocytes, Mononuclear - metabolism | MicroRNAs - isolation & purification | Animals | Buffaloes - genetics | Cells, Cultured | Real-Time Polymerase Chain Reaction - methods | Leukocytes, Mononuclear - cytology | MicroRNAs - metabolism | Buffaloes - metabolism | MicroRNAs - genetics | Cell Culture Techniques - methods
miScript primer assay | PBMCs | Small RNAs | TaqMan MicroRNA assay | Leukocytes, Mononuclear - metabolism | MicroRNAs - isolation & purification | Animals | Buffaloes - genetics | Cells, Cultured | Real-Time Polymerase Chain Reaction - methods | Leukocytes, Mononuclear - cytology | MicroRNAs - metabolism | Buffaloes - metabolism | MicroRNAs - genetics | Cell Culture Techniques - methods
Journal Article
Nature Reviews Cancer, ISSN 1474-175X, 12/2009, Volume 9, Issue 12, pp. 862 - 873
Currently, around 11 million people are living with a tumour that contains an inactivating mutation of TP53 (the human gene that encodes p53) and another 11...
WILD-TYPE P53 | BASE EXCISION-REPAIR | ONCOLOGY | SMALL-MOLECULE INHIBITORS | PROTEIN-PROTEIN INTERACTION | C-TERMINAL PEPTIDE | DNA-BINDING FUNCTION | HUMAN CANCER-CELLS | UBIQUITIN LIGASE ACTIVITY | TUMOR-SUPPRESSOR P53 | STRUCTURE-BASED DESIGN | Neoplasms - metabolism | Signal Transduction | Humans | Tumor Suppressor Protein p53 - metabolism | Antineoplastic Agents - chemistry | Drug Delivery Systems | Neoplasms - drug therapy | Genes, p53 | Neoplasms - genetics | Tumor Suppressor Protein p53 - agonists | Drug Design | Antineoplastic Agents - pharmacology | Mutation | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Physiological aspects | Development and progression | Tumor suppressor genes | Research | Drug therapy | Tumors
WILD-TYPE P53 | BASE EXCISION-REPAIR | ONCOLOGY | SMALL-MOLECULE INHIBITORS | PROTEIN-PROTEIN INTERACTION | C-TERMINAL PEPTIDE | DNA-BINDING FUNCTION | HUMAN CANCER-CELLS | UBIQUITIN LIGASE ACTIVITY | TUMOR-SUPPRESSOR P53 | STRUCTURE-BASED DESIGN | Neoplasms - metabolism | Signal Transduction | Humans | Tumor Suppressor Protein p53 - metabolism | Antineoplastic Agents - chemistry | Drug Delivery Systems | Neoplasms - drug therapy | Genes, p53 | Neoplasms - genetics | Tumor Suppressor Protein p53 - agonists | Drug Design | Antineoplastic Agents - pharmacology | Mutation | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Physiological aspects | Development and progression | Tumor suppressor genes | Research | Drug therapy | Tumors
Journal Article
NATURE REVIEWS DRUG DISCOVERY, ISSN 1474-1776, 04/2014, Volume 13, Issue 4, p. 256
The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more than half of all human tumours carrying mutations in this particular...
BIOTECHNOLOGY & APPLIED MICROBIOLOGY | PHARMACOLOGY & PHARMACY
BIOTECHNOLOGY & APPLIED MICROBIOLOGY | PHARMACOLOGY & PHARMACY
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 01/2011, Volume 8, Issue 1, pp. 25 - 37
Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other 50% of cases, the TP53 gene itself is not mutated but the p53...
WILD-TYPE P53 | CANCER-CELLS | LUNG-CANCER | TRANSCRIPTIONAL ACTIVITY | ONCOLOGY | INDUCED APOPTOSIS | CELL-CYCLE ARREST | MDM2 ANTAGONIST NUTLIN-3 | STRUCTURE-BASED DESIGN | TUMOR-SUPPRESSOR PATHWAY | SMALL-MOLECULE INHIBITOR | Genetic Therapy | Neoplasms - therapy | Neoplasms - genetics | Tumor Suppressor Protein p53 - antagonists & inhibitors | Humans | Tumor Suppressor Protein p53 - metabolism | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Mutation - genetics | Tumor Suppressor Protein p53 - genetics | Antimitotic agents | Usage | Gene mutations | Cancer cells | Tumor suppressor genes | Genetic aspects | Research | Antineoplastic agents | Health aspects
WILD-TYPE P53 | CANCER-CELLS | LUNG-CANCER | TRANSCRIPTIONAL ACTIVITY | ONCOLOGY | INDUCED APOPTOSIS | CELL-CYCLE ARREST | MDM2 ANTAGONIST NUTLIN-3 | STRUCTURE-BASED DESIGN | TUMOR-SUPPRESSOR PATHWAY | SMALL-MOLECULE INHIBITOR | Genetic Therapy | Neoplasms - therapy | Neoplasms - genetics | Tumor Suppressor Protein p53 - antagonists & inhibitors | Humans | Tumor Suppressor Protein p53 - metabolism | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Mutation - genetics | Tumor Suppressor Protein p53 - genetics | Antimitotic agents | Usage | Gene mutations | Cancer cells | Tumor suppressor genes | Genetic aspects | Research | Antineoplastic agents | Health aspects
Journal Article
The Journal of Physical Chemistry C, ISSN 1932-7447, 01/2014, Volume 118, Issue 3, pp. 1530 - 1539
Ionic liquid (IL) 1-ethyl-3-methylimidazolium ethyl sulfate [EMIM][EtSO4] has been immobilized in silica matrix by using nonhydrolytic one-pot sol–gel method,...
MATRIX | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | NETWORKS | GELATION | ELECTROLYTES | GEL | GLASS-TRANSITION | SOLVENTS | TEMPERATURE | SULFATE | IONOGELS
MATRIX | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | NETWORKS | GELATION | ELECTROLYTES | GEL | GLASS-TRANSITION | SOLVENTS | TEMPERATURE | SULFATE | IONOGELS
Journal Article
International Journal of Molecular Sciences, ISSN 1422-0067, 11/2019, Volume 20, Issue 23, p. 5996
Proteins that limit the activity of the tumour suppressor protein p53 are increasingly being targeted for inhibition in a variety of cancers. In addition to...
Journal Article
16.
Full Text
1784-P: Studying the Impact of Heterozygous Human INS Gene Mutation on Pancreatic ß Cell
Diabetes, ISSN 0012-1797, 06/2019, Volume 68, Issue Supplement 1, p. 1784
Journal Article
Journal of Chemical Information and Modeling, ISSN 1549-9596, 2019, Volume 59, Issue 6, pp. 2850 - 2858
The emergence of resistance against drugs that inhibit a particular protein is a major problem in targeted therapy. There is a clear need for rigorous methods...
PROTEIN SIDE-CHAIN | ACCURATE | CHEMISTRY, MEDICINAL | FREE-ENERGY LANDSCAPE | STABILITY | ACQUIRED-RESISTANCE | COMPUTER SCIENCE, INFORMATION SYSTEMS | KINASE INHIBITORS | MECHANISMS | DRUG-RESISTANCE | CHEMISTRY, MULTIDISCIPLINARY | COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS | ONCOGENIC MUTATIONS | BINDING | Drugs | Binding | Computer simulation | Computation | Affinity | Mutation | Substrates
PROTEIN SIDE-CHAIN | ACCURATE | CHEMISTRY, MEDICINAL | FREE-ENERGY LANDSCAPE | STABILITY | ACQUIRED-RESISTANCE | COMPUTER SCIENCE, INFORMATION SYSTEMS | KINASE INHIBITORS | MECHANISMS | DRUG-RESISTANCE | CHEMISTRY, MULTIDISCIPLINARY | COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS | ONCOGENIC MUTATIONS | BINDING | Drugs | Binding | Computer simulation | Computation | Affinity | Mutation | Substrates
Journal Article
NUCLEIC ACIDS RESEARCH, ISSN 0305-1048, 07/2019, Volume 47, Issue W1, pp. W482 - W489
The study of contact residues and interfacial waters of antibody-antigen (Ab-Ag) structures could help in understanding the principles of antibody-antigen...
COMPLEX | AFFINITY | CRYSTAL-STRUCTURE | VEGF | FAB | BIOCHEMISTRY & MOLECULAR BIOLOGY | Web Server Issue
COMPLEX | AFFINITY | CRYSTAL-STRUCTURE | VEGF | FAB | BIOCHEMISTRY & MOLECULAR BIOLOGY | Web Server Issue
Journal Article